Lanzhou Lansheng Blood Products

Lanzhou Lansheng Blood Products is a specialized Chinese biopharmaceutical company focused on the research, development, and large-scale production of plasma-derived therapeutics. As a key player in the regional blood products market, the company operates advanced plasma collection and fractionation facilities to manufacture essential treatments such as human albumin, intravenous immunoglobulin (IVIG), and coagulation factors. The company is a subsidiary of the Lanzhou Institute of Biological Products, which falls under the umbrella of the China National Biotec Group (CNBG) and Sinopharm. Its products are critical for treating conditions ranging from severe trauma and hypoproteinemia to primary immunodeficiencies and hemophilia.